Vera Therapeutics formally submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for atacicept, its leading investigational therapy for immunoglobulin A nephropathy (IgAN). The FDA has accepted the application for priority review and set a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. If approved, atacicept could be available for self-administered, once-weekly subcutaneous injection shortly thereafter.

The BLA is supported by data from the ORIGIN 3 Phase 3 trial, which met its primary endpoint at week 36. Patients treated with atacicept achieved a 46% reduction from baseline in 24-hour urine protein-to-creatinine ratio, with a 42% statistically significant improvement versus placebo. These results underscore atacicept’s potential to address excessive protein loss, a hallmark of Berger’s disease that can lead to kidney failure in half of diagnosed patients.

Analysts see atacicept entering a multi-billion-dollar market for autoimmune kidney diseases. In October 2025, Bank of America Securities forecast nominal peak sales of $3 billion by 2037, citing atacicept’s favorable mechanism of action against B-cell activating factor and APRIL. Investor interest has intensified on the prospect of a high-value therapy that could reshape treatment protocols for IgAN, which currently lacks broadly approved at-home injectable options.

Pricing strategy will be pivotal to atacicept’s success. A comparable FDA-approved therapy launched at approximately $30,000 per monthly course, setting a benchmark for Vera’s market entry. Competition is evolving: Novartis recently reported positive Phase 3 results for its oral agent iptacopan, which demonstrated superiority in slowing renal decline over two years. Vera must navigate reimbursement negotiations and formulary positioning to secure access in a landscape defined by escalating demand for novel IgAN treatments.